CD8A and neoplasm: Consistent with the strong increase in undifferentiated tumor-specific CD8+ T cells in blood, we further demonstrate by adoptive transfer experiments that blood after triple treatment represents a rich source of tumor antigen-specific CD8+ T cells with high functionality and proliferative capacity for ACT.